Nuvation Bio Reports Q1 2026 Results, $18.5M Taletrectinib Revenue
Nuvation Bio reports $18.5M taletrectinib revenue in Q1 2026 with 89.8% response rate in TKI-naïve ROS1 patients and 46.1-month...
Syndax Q1 Revenue Jumps 224% on Revuforj, Niktimvo Sales Growth
Syndax's Q1 revenue surged 224% year-over-year, driven by Revuforj and Niktimvo combined sales exceeding $104 million in the quarter.
Setmelanotide Wins European Commission Approval for Acquired Hypothalamic Obesity
Setmelanotide wins European Commission approval for acquired hypothalamic obesity, with 19.8% placebo-adjusted BMI reduction in clinical trials.
BioCryst Licenses Navenibart European Rights to Neopharmed Gentili for $70M
BioCryst licenses navenibart European rights to Neopharmed Gentili for $70M upfront plus $275M in regulatory and sales milestones.
AbbVie Awards RIME Therapeutics Recognition for Protein-Interaction Platform
AbbVie awards RIME Therapeutics recognition for its Disruptide Platform, targeting protein-protein interactions in T cell biology and immunology.
Alvotech Names Lisa Graver as General Counsel, Relocating to Reykjavik
Alvotech Names Lisa Graver as General Counsel, relocating to Reykjavik as the biosimilar company shifts from build-phase to litigation...
Cue Biopharma Names Shao-Lee Lin as CEO to Lead Clinical-Stage Transformation
Shao-Lee Lin named CEO of Cue Biopharma to lead clinical-stage transformation with Phase 2 anti-IgE allergy program and early...
Pacira Posts 5% Revenue Growth as Pipeline Nears Key Data Readouts
Pacira's pipeline approaches critical data readouts including ZILRETTA shoulder OA Phase 3 results expected before year-end, with multiple binary...
Syndax Exceeds $100M Quarterly Sales; Revumenib Post-Transplant Rate Rises to 48%
Revumenib post-transplant rate rises to 48% as Syndax exceeds $100M quarterly sales, reshaping the commercial trajectory of its KMT2A-rearranged...
Setmelanotide Gains European Commission Approval for Acquired Hypothalamic Obesity
Setmelanotide gains European Commission approval for acquired hypothalamic obesity, delivering 19.8% placebo-adjusted BMI reduction across 120 patients.